Literature DB >> 12919091

Glomerular infiltration by CXCR3+ ICOS+ activated T cells in chronic allograft nephropathy with transplant glomerulopathy.

E Akalin1, S Dikman, B Murphy, J S Bromberg, W W Hancock.   

Abstract

The pathogeneses of chronic allograft nephropathy (CAN), a leading cause of allograft failure, and one of its complications, transplant glomerulopathy (TGP), are unknown. Immunohistologic analysis of human renal transplant biopsies showed expression of inducible costimulator (ICOS), the chemokine receptor CXCR3, and its ligands, Mig and IP-10, by intraglomerular and periglomerular leukocytes in biopsies with CAN and TGP but not CAN alone. ICOS and CXCR3 are both characteristics of activated, effector T cells, suggesting different pathogenetic mechanisms underlying TGP vs. CAN. We conclude that targeting of specific chemokine and chemokine receptor pathways and/or ICOS may have clinical application in the prevention and treatment of TGP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12919091     DOI: 10.1034/j.1600-6143.2003.00151.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  10 in total

1.  Polyomavirus BK Induces Inflammation via Up-regulation of CXCL10 at Translation Levels in Renal Transplant Patients with Nephropathy.

Authors:  Ashraf Kariminik; Shahriar Dabiri; Ramin Yaghobi
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

2.  Probabilistic (Bayesian) modeling of gene expression in transplant glomerulopathy.

Authors:  Eric A Elster; Jason S Hawksworth; Orlena Cheng; David B Leeser; Michael Ring; Douglas K Tadaki; David E Kleiner; John S Eberhardt; Trevor S Brown; Roslyn B Mannon
Journal:  J Mol Diagn       Date:  2010-08-05       Impact factor: 5.568

3.  A pilot trial targeting the ICOS-ICOS-L pathway in nonhuman primate kidney transplantation.

Authors:  D J Lo; D J Anderson; M Song; F Leopardi; A B Farris; E Strobert; S Chapin; B Devens; E Karrer; A D Kirk
Journal:  Am J Transplant       Date:  2015-02-20       Impact factor: 8.086

4.  CXCR3 is involved in tubulointerstitial injury in human glomerulonephritis.

Authors:  Stephan Segerer; Bernhard Banas; Markus Wörnle; Holger Schmid; Clemens D Cohen; Matthias Kretzler; Matthias Mack; Eva Kiss; Peter J Nelson; Detlef Schlöndorff; Hermann-Josef Gröne
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

5.  Effector functions of donor-reactive CD8 memory T cells are dependent on ICOS induced during division in cardiac grafts.

Authors:  A D Schenk; V Gorbacheva; M Rabant; R L Fairchild; A Valujskikh
Journal:  Am J Transplant       Date:  2008-10-31       Impact factor: 8.086

Review 6.  Late kidney allograft loss: what we know about it, and what we can do about it.

Authors:  Anthony M Jevnikar; Roslyn B Mannon
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

7.  The clinical and genomic significance of donor-specific antibody-positive/C4d-negative and donor-specific antibody-negative/C4d-negative transplant glomerulopathy.

Authors:  Nicole Hayde; Yi Bao; James Pullman; Bin Ye; R Brent Calder; Monica Chung; Daniel Schwartz; Michelle Lubetzky; Maria Ajaimy; Graciela de Boccardo; Enver Akalin
Journal:  Clin J Am Soc Nephrol       Date:  2013-09-12       Impact factor: 8.237

Review 8.  Transplant glomerulopathy.

Authors:  Edward J Filippone; Peter A McCue; John L Farber
Journal:  Mod Pathol       Date:  2017-10-13       Impact factor: 7.842

Review 9.  The specificity of acute and chronic microvascular alterations in renal allografts.

Authors:  Edward J Filippone; John L Farber
Journal:  Clin Transplant       Date:  2013-10-01       Impact factor: 2.863

10.  Integrative Analyses of Circulating Small RNAs and Kidney Graft Transcriptome in Transplant Glomerulopathy.

Authors:  Canan Kuscu; Manjari Kiran; Akram Mohammed; Cem Kuscu; Sarthak Satpathy; Aaron Wolen; Elissa Bardhi; Amandeep Bajwa; James D Eason; Daniel Maluf; Valeria Mas; Enver Akalin
Journal:  Int J Mol Sci       Date:  2021-06-09       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.